Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled Trial to Evaluate Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) in Comparison With a Semi Selective Semipermeable Membrane (Standard AN-69) in COVID-19 Associated Acute Kidney Injury: oXAKI-COV Study.

NCT04597034 is registered in ClinicalTrials.gov with Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran as lead sponsor.

NCT NCT04597034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04597034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled Trial to Evaluate Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) in Comparison With a Semi Selective Semipermeable Membrane (Standard AN-69) in COVID-19 Associated Acute Kidney Injury: oXAKI-COV Study.
Lead sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase
Not applicable
Overall status
Unknown status
Start date
October 2, 2020
Completion date
March 30, 2022
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aki, covid19